# Mesoblast Limited American (MESO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $17.32, market value $2.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Mesoblast Limited American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 18.7×**. Each dollar of revenue is priced at 18.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.0×**. The shares trade at 4.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.3%** (5-yr avg -0.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 86.1%**. Mesoblast Limited American keeps 86.1% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -42.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -47.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -10.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -7.9%**. Return on all capital, debt included, is -7.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -7.4%**. Each dollar of assets produces -7.4% of profit.

## Growth
- **Revenue growth (1 yr): 599.2%** (3-yr 152.1%/yr, 5-yr 74.5%/yr). Revenue grew 599.2% over the last year, against 74.5% a year compounded over five years: growth is accelerating.

## Financial health
- **Debt to equity: 0.22**. Debt is 0.22 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Mesoblast Limited American holds more cash than debt.
- **Interest coverage: -2.6×**. Operating profit covers interest only -2.6×: fragile.
- **Current ratio: 2.43** (quick 2.09). Current assets cover the next year's liabilities 2.43 times.
- **Altman Z-score: 7.74**. A Z-score of 7.74 places the company in the safe zone for bankruptcy risk.

## Dividends
- **Dividend: none**. Mesoblast Limited American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (2 analysts). 2 analysts cover Mesoblast Limited American; the consensus is buy, with an average price target of $37.00 (+114% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 28.1%** (YTD -4.0%, 3-mo 24.2%). The shares are up 28.1% over twelve months including dividends.
- **From 52-week high: -19.4%** (32.7% above the low). Trading 19% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 1.51** (volatility 56%). Beta of 1.51 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MESO · Page: https://foliofundamentals.com/stocks/meso

Not investment advice.